Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7808357 | 0.78 | MAOA (0.52) | SLC6A4SLC6A3SLC6A2HRH3OPRL1 | |
| SCHEMBL6138472 | 0.74 | MAOA (0.48) | OPRL1OPRM1SIGMAR1 | |
| SCHEMBL4591914 | 0.73 | CHRM2 (0.45) | CHRM2CHRM1CHRM3LMNA | |
| Hydrochloric Acid SCHEMBL30175029 | 0.72 | MAOA (0.47) | OPRL1OPRM1 | |
| SCHEMBL14285983 | 0.71 | ADRB2 (0.48) | SLC6A4SLC6A3SLC6A2OPRL1OPRM1 | |
| SCHEMBL13075727 | 0.71 | MAOA (0.45) | SLC6A4OPRL1OPRM1 | |
| SCHEMBL27353392 | 0.69 | ADRB2 (0.50) | SLC6A4SLC6A3SLC6A2OPRL1OPRM1 | |
| Hydrochloric Acid SCHEMBL28705458 | 0.66 | MEN1 (0.41) | SLC6A4SLC6A3SLC6A2OPRL1OPRM1 | |
| SCHEMBL7121075 | 0.65 | SLC6A3 (0.53) | SLC6A4SLC6A3SLC6A2OPRL1CHRM2 | |
| SCHEMBL1022483 | 0.65 | OPRM1 (0.54) | OPRM1DRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118108-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2012-11-14 | — | — | EP | disclosed |
| CN-101730698-B | Compounds for the treatment of hepatitis c | BRISTOL MYERS SQUIBB CO | 2012-09-05 | — | — | CN | disclosed |
| CN-101730698-A | Compounds for the treatment of hepatitis c | BRISTOL MYERS SQUIBB CO | 2010-06-09 | — | — | CN | disclosed |
| EP-2118108-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2009-11-18 | — | — | EP | disclosed |
| US-7541353-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080226591-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| WO-2008112848-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080226591-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | SLC6A4 4222/4885SLC6A3 2857/4885SLC6A2 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.